The Democratic Republic of the Congo (DRC) hopes to receive its first doses of an mpox vaccine by next week, following promises from the United States and Japan to help it fight its outbreak, the Congolese health minister said on Monday.
The World Health Organization last week declared mpox a global public health emergency for the second time in two years as a new variant of the disease, known as clade Ib, spread rapidly in Africa.
What is #mpox? Learn more👉https://t.co/EMCaukiTEm pic.twitter.com/fTbKi3BOiv
— World Health Organization (WHO) (@WHO) August 19, 2024
In a news conference on Monday, Health Minister Samuel Roger Kamba Mulamba said that Japan and the United States had pledged vaccines to Congo.
“We’ve just finished discussions with USAID and the U.S. government… I hope that by next week we’ll be able to see the vaccines arrive,” he told reporters.
Their arrival would help to address a huge inequity that left African countries with no access to the two shots used in a 2022 global mpox outbreak, while the vaccines were widely available in Europe and the United States.
Earlier on Monday, Japan’s Ministry of Health, Labour and Welfare said in an emailed statement to Reuters that it was preparing to provide Congo with supplies of mpox vaccines and needles in cooperation with the World Health Organization and other partners.
The ministry “intends to provide as much support as possible”, Masano Tsuzuki, section chief of its division of infectious disease prevention and control, said.
JUST IN: Mpox Outbreak Reaches 14 Total African Countries With Cases Rising To 15,000.
Mpox, short for Monkeypox, is believed to be airborne and can lead to serious health issues and death.
Travelers to and from African countries have been warned to visit with extreme caution. https://t.co/7l53u1cwjz pic.twitter.com/EztoPNesEW
— JAKE (@JakeGagain) August 14, 2024
Japan-based KM Biologics is one of the manufacturers of an mpox vaccine. Denmark’s Bavarian Nordic makes another vaccine, called Jynneos, for the disease. Japan holds a stockpile of the KM Biologics vaccine.
Outside clinical trials, neither of the shots have been available in Congo or across Africa, where the disease has been endemic for decades.
The global vaccine group Gavi said last week it had up to $500 million to spend on getting shots to countries affected by Africa’s escalating mpox outbreak.
“Gavi has offered to make the vaccines available and we agreed,” Congo’s health minister said.
Mpox, a viral infection that causes pus-filled lesions and flu-like symptoms, is usually mild but can kill. Two strains are spreading in Congo – the endemic form of the virus, clade I, and the new clade Ib offshoot.
The virus transmits through close physical contact, including sexual contact, but unlike previous global pandemics such as COVID-19, there is no evidence it spreads easily through the air.
On Monday, the Philippines health department said it has detected a new case of the mpox virus in the country, the first since December last year, adding it was awaiting test results before being able to determine the strain. The patient was a 33-year-old Filipino male who had no travel history outside the Philippines.
(Reuters)
